<DOC>
	<DOCNO>NCT00283088</DOCNO>
	<brief_summary>The purpose trial evaluate safe use tissue plasminogen activator ( tPA ) within 6 hour stroke onset combine hypothermia .</brief_summary>
	<brief_title>Intravenous Thrombolysis Plus Hypothermia Acute Treatment Ischemic Stroke</brief_title>
	<detailed_description>A stroke usually cause blockage one arteries carry blood brain . Research show tissue plasminogen activator ( tPA ) —a naturally occur protein open blocked artery dissolve blood clots—activates body 's ability dissolve recently form blood clot reduce prevents brain damage cause stroke . The Food Drug Administration ( FDA ) approve use tPA people stroke take within 3 hour stroke onset , arrive hospital 3 hour stroke onset . Researchers believe low body temperature ( hypothermia ) may beneficial stroke happen hypothermia may prevent brain injury , may make stroke less damaging . In particular , hypothermia may make possible use tPA later 3 hour stroke begin . This study determine safe use tPA within 6 hour start stroke combine hypothermia . Patients receive standard stroke evaluation , include blood test , compute tomography ( CT ) scan , complete physical neurological examination , electrocardiogram ( EKG ) determine eligibility study . Participants randomly assign study group base stroke begin . Those arrive hospital le 3 hour stroke onset receive tPA alone tPA cooling ( hypothermia ) . Those arrive hospital 3 6 hour stroke onset assign 1 4 groups—receiving either tPA alone , tPA cooling , cool alone , standard medical care . Length participation ( include observation patient leave hospital ) 90 day . This study part Specialized Program Translational Research Acute Stroke ( SPOTRIAS ) , allow researcher enhance initiate translational research ultimately benefit stroke patient treat patient le 2 hour , find way treat additional patient later .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Hypothermia</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Age 18 80 All eligibility criterion tPA administration acute ischemic stroke outline NINDS tPA Guidelines meet exception time onset Stroke onset within 6 hour prior plan start tPA Any subtype ischemic stroke NIHSS &lt; 7 time hypothermia begin Etiology ischemic stroke Item 1a NIHSS &gt; 1 time enrollment Symptoms resolve NIHSS &lt; 7 time hypothermia begin Contraindications hypothermia , patient know hematologic dyscrasia affect thrombosis , ( cryoglobulinemia , Sickle cell disease , serum cold agglutinin ) , vasospastic disorder Raynaud 's thromboangiitis obliterans . Known comorbid condition likely complicate therapy , e.g. , endstage cardiomyopathy , uncompensated arrhythmia , myopathy , liver disease severe enough elevate bilirubin , history pelvic abdominal mass likely compress inferior vena cava , IVC filter , dementia severe enough prevent valid consent , endstage AIDS , know thyroid deficiency , know renal insufficiency likely impair meperidine ( Demerol® ) clearance Intracerebral hematoma Any intraventricular hemorrhage SBP &gt; 185 &lt; 100 ; DBP &gt; 110 &lt; 50 mmHg Pregnancy woman childbearing potential ( must pregnancy test , urine blood , prior therapy ) . Medical condition likely interfere patient assessment Known allergy meperidine ( Demerol® ) Currently take MAOI class medication use within previous 14 day Life expectancy &lt; 3 month Not likely available longterm followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>stroke</keyword>
	<keyword>hypothermia</keyword>
	<keyword>cool</keyword>
	<keyword>tissue plasminogen activator</keyword>
	<keyword>tPA</keyword>
	<keyword>thrombolysis</keyword>
</DOC>